Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104338 · ClinicalTrials.gov registry record · Phase 2
Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00104338 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 45 participants.
The verdict
NCT00104338, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.
Interventions
- DRUG FK778
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104338
The ClinicalTrials.gov registry entry for NCT00104338 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FK778 is the first listed.
NCT00104338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00104338 about?
NCT00104338 is a clinical study titled "Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy". The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.
What is the current status of trial NCT00104338?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2005-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00104338?
The interventions under investigation include: FK778 (DRUG).
Who is sponsoring clinical trial NCT00104338?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.